DRUG DOSING GUIDELINES IN PATIENTS WITH RENAL-FAILURE

被引:1
|
作者
SWAN, SK
BENNETT, WM
机构
来源
WESTERN JOURNAL OF MEDICINE | 1992年 / 156卷 / 06期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The metabolism and excretion of many drugs and their pharmacologically active metabolites depend on normal renal function. Accumulation and toxicity can develop rapidly if dosages are not adjusted in patients with impaired renal function. In addition, many drugs that are not dependent on the kidneys for elimination may exert untoward effects in the uremic milieu of advanced renal disease. A familiarity with basic pharmacologic principles and a systematic approach are necessary when adjusting drug dosages in patients with abnormal kidney function. The distinct steps involve calculating the patient's glomerular filtration rate, choosing and administering a loading dose, determining a maintenance dose, and a decision regarding monitoring of drug concentrations. If done properly, therapy in renal patients should achieve the desired pharmacologic effects while avoiding drug toxicity. Physicians must not oversimplify the pharmacologic complexities presented by patients with renal failure by relying excessively on nomograms and "cookbook" equations. In addition to a reduced glomerular filtration rate, patients with renal disease often have alterations in pharmacokinetics such as bioavailability, protein binding, hepatic biotransformation, and volume of distribution. An awareness of biologically active or toxic metabolites of parent compounds that accumulate when the glomerular filtration rate is reduced is also necessary to avoid toxicity. The effects of dialysis on drug elimination and the need for supplemental dosing are additional considerations in patients undergoing renal replacement therapy.
引用
收藏
页码:633 / 638
页数:6
相关论文
共 50 条
  • [31] DRUG-THERAPY IN RENAL-FAILURE
    BERTHOUX, FC
    LYON MEDICAL, 1979, 242 (20): : 669 - 680
  • [32] ACTIVE DRUG METABOLITES AND RENAL-FAILURE
    DRAYER, DE
    AMERICAN JOURNAL OF MEDICINE, 1977, 62 (04): : 486 - 489
  • [33] RENAL-FAILURE AND DRUG-METABOLISM
    BALANT, LP
    THERAPIE, 1987, 42 (04): : 393 - 397
  • [34] ESTIMATION OF DRUG ELIMINATION IN RENAL-FAILURE
    PERRIER, D
    GIBALDI, M
    JOURNAL OF CLINICAL PHARMACOLOGY, 1973, 13 (11-1): : 458 - 462
  • [35] DRUG-METABOLISM IN RENAL-FAILURE
    STERN, A
    COMPENDIUM ON CONTINUING EDUCATION FOR THE PRACTICING VETERINARIAN, 1983, 5 (11): : 913 - &
  • [36] SELENIUM IN RENAL-FAILURE PATIENTS
    MILLY, K
    WIT, L
    DISKIN, C
    TULLEY, R
    NEPHRON, 1992, 61 (02): : 139 - 144
  • [37] SURGERY IN PATIENTS WITH RENAL-FAILURE
    KOBRYN, A
    CHMURA, A
    GIEORGIJEWSKI, J
    MATUSZKIEWICZ, J
    KLEPACKA, J
    LAZOWSKI, T
    ROWINSKI, W
    SICINSKI, A
    ORLOWSKI, T
    MINERAL AND ELECTROLYTE METABOLISM, 1986, 12 (04) : 264 - 264
  • [38] ANESTHESIA FOR PATIENTS ON RENAL-FAILURE
    ESTAFANO.FG
    ANAESTHESIST, 1972, 21 (12): : 519 - 519
  • [39] PHARMACOKINETICS IN PATIENTS WITH RENAL-FAILURE
    MAHER, JF
    CLINICAL NEPHROLOGY, 1984, 21 (01) : 39 - 46
  • [40] MUCORMYCOSIS IN PATIENTS WITH RENAL-FAILURE
    GUPTA, KL
    RADOTRA, BD
    SAKHUJA, V
    BANERJEE, AK
    CHUGH, KS
    RENAL FAILURE, 1990, 11 (04) : 195 - 199